Clinical Trial Update: Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of arsenic trioxide and ascorbic acid in myelodysplastic syndromes was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Arsenic Trioxide (Trisenox) (arsenic trioxide)
• Ascorbic acid (Vitamin C)

Snippet

Sponsor: Fondazione Italiana Sindromi Mielodisplastiche-ETS | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED